Utibron Neohaler (indacaterol/ glycopyrrolate) Inhalation Power

Overview

The Utibron Neohaler (indacaterol and glycopyrrolate) is used for the long-term treatment of COPD symptoms. It is a combination of indacaterol, a long-acting beta2-adrenergic agonist (LABA), and glycopyrrolate, an anticholinergic/antimuscarinic agent (LAMA). Both work to open the airways and relax muscles around the lungs. These medications in combination can provide maintenance treatment for COPD. LABAs relax the smooth muscles around the lungs and anticholinergic medications or LAMAs perform a similar function by specifically blocking the action of acetylcholine creating an analogous effect. Together, they work to decrease common symptoms of COPD, such as wheezing, chest tightness, and shortness of breath.

What are the ingredients in Utibron Neohaler?

The active ingredients in the Utibron Neohaler are indacaterol maleate and glycopyrrolate, the LABA and LAMA medications.

How does Utibron Neohaler work?

The Utibron Neohaler is a combination of a LABA medication and a LAMA medication or anticholinergic. The LABA medication (indacaterol) works as a bronchodilator, relaxing the smooth muscles around the airways and lungs. The anticholinergic (glycopyrrolate) acts as an inhibitor of acetylcholine, inhibiting its effects. Acetylcholine acts in nerve cells that control the involuntary muscle movements of the lungs, urinary tract, and gastrointestinal tract, among others. Acetylcholine is a chemical messenger (neurotransmitter) that passes signals from one nerve cell to another, instructing the body on how its muscles should work.

By blocking this messenger, the anticholinergic in the Utibron Neohaler can help the muscles around the lungs and airways to relax. Both parts of the medication work in similar ways, with the overall goal being muscle relaxation. When these muscles are relaxed, common COPD symptoms like chest tightness, shortness of breath, and wheezing can be improved.

What are the possible side effects of Utibron Neohaler?

Throughout multiple clinical trials evaluating the safety and efficacy of the Utibron Neohaler, the most common side effects were runny nose, back pain, high blood pressure, diarrhea, headache and sore throat. There is a possibility of experiencing an allergic reaction when using the Utibron Neohaler. Alert your doctor immediately, or contact your local emergency department if you have any signs of reaction, including:

  • Rash
  • Hives
  • Swelling of tongue, lips and/or face
  • Trouble breathing or swallowing

If you notice a sudden shortness of breath right after using the medication, it is important to alert your doctor immediately or contact your local emergency department, as this could be life-threatening.

Other serious side effects include developing new or worsened eye issues, such as acute narrow-angle glaucoma, as well as developing new or worsening urinary retention difficulties, heart problems or developing changes in laboratory blood levels. Alert your doctor if you notice any of the following symptoms:

  • Eye pain or discomfort
  • Nausea or vomiting
  • Red eyes
  • Seeing bright colors or halos around lights
  • Blurred vision
  • Painful urination
  • Urinating frequently
  • Difficulty urinating including urinating in drips or weak streams
  • Increased blood pressure
  • Fast or irregular heartbeat or palpitations
  • Chest pain
  • High levels of blood sugar (hyperglycemia)
  • Low levels of potassium (hypokalemia)
  • Muscle spasms or weakness

This is not an exhaustive list of all potential side effects of the Utibron Neohaler. Talk to your healthcare provider or pharmacist for further information.

Things to note about Utibron Neohaler

The Utibron Neohaler is not indicated for individuals with asthma who take LABA medications, including indacaterol, as an increased in death related to asthma complications can occur. It is also not known if LABA medications increase the risk of death in people with COPD over time.

The Utibron Neohaler is indicated for adults with COPD, and it is not known if it is safe or effective for individuals with asthma or children. There are situations in which you should not take the Utibron Neohaler, including if you are allergic to the indacaterol or glycopyrrolate in the Utibron Neohaler, or any of its other ingredients. The medication includes an inhaler (neohaler) and indacaterol/glycopyrrolate capsules to be used in the neohaler.

The Utibron Neohaler does not work to treat sudden and severe symptoms. For this reason, those using the Utibron Neohaler should still also have a rescue inhaler (beta2-agonist medicine) on hand in case of sudden and severe symptoms. Alert your doctor if you notice you are using your rescue inhaler more frequently than usual, or if it’s not working as well.

Do not use the Utibron Neohaler until your healthcare provider or pharmacist shows you how to properly use the treatment. Step-by-step instructions can be found on the prescribing information, and should be reviewed each time a new prescription is filled.

The capsules that come with the Utibron Neohaler should never be swallowed or taken by mouth, and should only be used with the neohaler provided. A new neohaler should be used each time you receive a new prescription. The inhaler does not need to be cleaned, but the mouthpiece can be wiped with a clean, dry, lint-free cloth. The Utibron Neohaler must be kept dry at all times, and the inhaler and blister-packaged capsules should be stored at room temperature (between 68 and 77 degrees Fahrenheit). Do not take any capsules out of the packaging until you are ready to use them, and peel back the foil when removing, do not push the capsules out of the packaging. Do not use the capsules with other inhalers nor share your inhaler with anyone else, even if they have similar symptoms. The medication can affect others differently and must be prescribed on an individual basis by providers.

Before starting Utibron Neohaler tell your provider about all medical conditions you may have, and treatments you are taking including:

  • Heart problems
  • High Blood Pressure
  • History of Seizure
  • Thyroid Problems
  • History of Diabetes
  • Liver Problems
  • Kidney problems
  • Bladder or Prostate problems
  • Eye problems such as glaucoma
  • Other medical conditions
  • If you are pregnant or planning to become pregnant
  • If you are breastfeeding or planning to breastfeed
  • Allergic to any of the ingredients in the Utibron Neohaler, as well as any ingredients in other medications or foods
  • If you are taking other anticholinergic or LABA medications, as these can work in additive ways to one another and cause serious problems
  • If you are taking any over-the-counter medications, vitamins, or herbal supplements

Do not stop taking the Utibron Neohaler or other COPD medications without talking to your healthcare provider first.

Dosing information

The Utibron Neohaler should be taken twice-daily, with one capsule taken with the inhaler in the morning, and another capsule in the evening. The capsules contain 27.5 mcg of indacaterol and 15.6 mcg of glycopyrrolate in a powder. No more than one capsule should be taken at a time. Use only as your provider directs. Do not take more than twice a day. The inhaler can be opened after use, and if no powder is left in the capsule, the full dose has been administered.

For additional information on Utibron Neohaler, read the full prescribing information here.

Written by: Anna Nicholson | Last reviewed: July 2015.
View References
  1. Utibron Neohaler Prescribing Information. Novartis Pharmaceuticals Corporation. Jan 2017. Available from: https://www.utibron.com/Utibron-Prescribing-Information.pdf